



RESEARCH AND FUNDING



Grants for the Department of Pediatrics 2016-17

NATIONAL INSTITUTES OF HEALTH

DIVISION	NAME	AGENCY TITLE	GRANT TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	Tailoring Clinical Interventions for Adolescent Relationship Abuse	\$161,504.00	\$12,920.00	\$174,424.00	14-Apr-14	31-Mar-19
Adolescent Medicine	Miller, Elizabeth	National Institute of Health	College Health Center-Based Alcohol and Sexual Violence Intervention	\$413,215.00	\$208,390.00	\$621,605.00	20-Aug-14	31-Jul-19
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	Adolescent Research in Community Postdoctoral Training Program	\$301,974.00	\$14,778.00	\$316,752.00	01-May-16	30-Apr-21
Adolescent Medicine	Radovic, Ana	National Institutes of Health	Social Media Intervention for Adolescents with Depression and Anxiety and Their Parents to Increase Use of Mental Health Services	\$164,760.00	\$13,139.00	\$177,899.00	01-Sep-16	31-Aug-20
Bone Marrow Transplant/Cell Therapy	Byersdorfer, Craig	National Institutes of Health	Changes in T-Cell Metabolism during Graft-Versus-Host Disease	\$144,544.00	\$11,564.00	\$156,108.00	01-May-16	30-Apr-20
Bone Marrow Transplant/Cell Therapy	Szabolcs, Paul	National Institutes of Health	Cadaveric Donor Lung and Bone Marrow Transplantation in Immunodeficiency Diseases	\$629,031.00	\$330,065.00	\$959,096.00	06-Jul-16	30-Jun-21
Cystic Fibrosis Research Center	Frizzell, Raymond	National Institutes of Health	Chaperone Actions in CFTR Biogenesis	\$222,500.00	\$120,150.00	\$342,650.00	01-May-16	30-Apr-18
Cystic Fibrosis Research Center	Frizzell, Raymond	National Institutes of Health	Basic and Translational Studies of Cystic Fibrosis, Administrative Core	\$677,185.00	\$360,820.00	\$1,038,005.00	01-Jun-16	31-May-18
Emergency Medicine	Manole, Mioara	National Institutes of Health	CYP 450-Mediated CBF Dysregulation and Neurotoxicity in Pediatric Cardiac Arrest	\$207,500.00	\$107,000.00	\$314,500.00	10-Sep-13	31-May-18
Endocrinology	Becker, Dorothy	National Institutes of Health	Trial to Reduce IDDM in the Genetically at Risk: A Nutritional Primary Prevention	\$0.00	\$0.00	\$0.00	01-Jul-11	30-Jun-17
Endocrinology	Becker, Dorothy	National Institutes of Health	Prediction and Prevention of Type 1 Diabetes (TrialNet)	\$340,068.00	\$161,497.00	\$501,565.00	01-Aug-14	30-Apr-19
Endocrinology	Dong, Hengjiang	National Institutes of Health	Fox01 in Beta-Cell Compensation	\$211,992.00	\$93,055.00	\$305,047.00	15-Jan-14	30-Nov-17
Endocrinology	Muzumdar, Radhika	National Institutes of Health	Novel Mitochondria-Associated Peptide and Beta-Cell Function in Aging	\$0.00	\$0.00	\$0.00	15-Sep-15	31-Aug-17
Endocrinology	Muzumdar, Radhika	National Institutes of Health	Research Training in Pediatric Endocrinology	\$179,084.00	\$15,307.00	\$194,391.00	01-Jul-16	30-Jun-21
General Academic Pediatrics	Bogen, Debra	Health Resources and Services Administration	University of Pittsburgh HRSA NRSA T32 Primary Care Research Training Program	\$356,030.00	\$23,447.00	\$379,477.00	01-Jul-16	30-Jun-22
General Academic Pediatrics	Hoberman, Alejandro	National Institutes of Health	Efficacy of Tympanostomy Tubes for Children with Recurrent Acute Otitis Media	\$753,106.00	\$189,823.00	\$942,929.00	14-Jul-15	30-Jun-20
General Academic Pediatrics	Rajakumar, Kumaravel	National Institutes of Health	Vitamin D and Vascular Function in Obese Children	\$478,236.00	\$188,268.00	\$666,504.00	01-Feb-13	31-Jan-18
General Academic Pediatrics	Rajakumar, Kumaravel	National Institutes of Health	Administrative Supplements for Research on Dietary Supplements	\$64,935.00	\$35,065.00	\$100,000.00	01-Jul-16	31-Jan-17
General Academic Pediatrics	Ray, Kristin	National Institutes of Health	Optimizing Pediatric Subspecialty Care through Telemedicine and e-Consultations	\$144,545.00	\$11,502.00	\$156,047.00	01-Apr-17	31-Mar-22
General Academic Pediatrics	Shaikh, Nader	National Institutes of Health	Corticosteroids for Children with Febrile Urinary Tract Infections	\$0.00	\$0.00	\$0.00	01-Apr-11	31-Mar-18
General Academic Pediatrics	Shaikh, Nader	National Institutes of Health	Efficacy of Antibiotics in Children with Sinusitis: Which Subgroups Benefit?	\$778,191.00	\$197,179.00	\$975,370.00	01-Jun-15	31-May-20
Gastroenterology	Husain, Sohail	National Institutes of Health	HDACs in Pancreatic Recovery after Injury	\$264,300.00	\$135,080.00	\$399,380.00	01-Jul-14	30-Jun-18
Gastroenterology	Husain, Sohail	National Institutes of Health	Calcineurin in Pancreatitis	\$276,697.00	\$126,159.00	\$402,856.00	01-Jul-16	30-Jun-21
Gastroenterology	Lowe, Mark	National Institutes of Health	Institutional Research Training in Pediatrics Gastroenterology	\$0.00	\$0.00	\$0.00	01-Aug-11	31-Jul-17
Gastroenterology	Squires, Robert	National Institutes of Health	A Multicenter Group to Study Acute Liver Failure in Children	\$0.00	\$0.00	\$0.00	30-Sep-10	31-Aug-17

NATIONAL INSTITUTES OF HEALTH (continued)

DIVISION	NAME	AGENCY TITLE	GRANT TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Gastroenterology	Squires, Robert	National Institutes of Health	Pittsburgh Cholestatic Liver Disease Consortium	\$198,832.00	\$105,480.00	\$304,312.00	10-Aug-14	31-May-19
Genetics	Goetzman, Eric	National Institutes of Health	Regulation of Mitochondrial Metabolism by Lysine Acylation	\$264,200.00	\$131,050.00	\$395,250.00	01-Jun-16	31-May-21
Genetics	Nicholls, Robert	National Institutes of Health	Gene Imprinting and Obesity, a New Pig Model	\$0.00	\$0.00	\$0.00	08-Aug-14	31-Jul-17
Genetics	Vockley, Gerard	National Institutes of Health	Inborn Errors of Long Chain Fat Metabolism	\$238,670.00	\$115,003.00	\$353,673.00	01-Apr-16	31-Mar-20
Genetics	Vockley, Gerard	National Institutes of Health	Branched Chain acyl-CoA Metabolism and Disease	\$306,779.00	\$154,861.00	\$461,640.00	01-Jul-16	30-Jun-20
Hematology/Oncology	Lucas, Peter	National Institutes of Health	GPCR Signaling through a Novel NF-kB Pathway	\$254,498.00	\$130,502.00	\$385,000.00	01-Feb-13	31-Jan-18
Hematology/Oncology	Prochownik, Edward	National Institutes of Health	Control of Metabolism and Energy-Sensing Pathways by c-Myc	\$232,489.00	\$92,633.00	\$325,122.00	20-Jun-14	31-May-19
Infectious Diseases	Brown, Judy	National Institutes of Health	Viral Triggers of Celiac Disease	\$28,240.00	\$0.00	\$28,240.00	14-Sep-16	13-Sep-19
Infectious Diseases	Campfield, Brian	National Institutes of Health	A Critical Role of Follistatin-Like Protein-1 in Lung Homeostasis	\$125,350.00	\$10,028.00	\$135,378.00	01-Sep-15	31-May-20
Infectious Diseases	Dermody, Terence	National Institutes of Health	Molecular Basis of Reovirus Pathogenesis	\$297,779.00	\$142,989.00	\$440,768.00	08-Aug-16	31-Jul-20
Infectious Diseases	Dermody, Terence	National Institutes of Health	Molecular Basis of Pediatric Diseases	\$0.00	\$0.00	\$0.00	01-Dec-11	30-Nov-17
Infectious Diseases	Dermody, Terence	National Institutes of Health	Cell Biology of Reovirus Infection	\$378,762.00	\$86,686.00	\$465,448.00	01-Jun-16	31-Mar-19
Infectious Diseases	Dermody, Terence	National Institutes of Health	Reovirus Attachment Mechanisms	\$308,761.00	\$105,683.00	\$414,444.00	01-Jun-16	30-Apr-20
Infectious Diseases	Dermody, Terence	National Institutes of Health	Chikungunya Virus Replication and Pathogenesis	\$662,218.00	\$104,131.00	\$766,349.00	01-Jun-16	28-Feb-21
Infectious Diseases	Dermody, Terence	National Institutes of Health	Molecular Basis of Pediatric Diseases, Supplement #1	\$261,887.00	\$20,951.00	\$282,838.00	01-Dec-15	30-Nov-17
Infectious Diseases	Dermody, Terence	National Institutes of Health	Basic/Translational Research Training for CHP Pediatric Fellows	\$369,781.00	\$25,952.00	\$395,733.00	01-May-13	30-Apr-18
Infectious Diseases	Knowlton, Jonathan	National Institutes of Health	Mechanisms of Noncytolytic Reovirus Egress	\$28,240.00	\$0.00	\$28,240.00	01-Jul-16	30-Jun-20
Infectious Diseases	Lenemann, Nicholas	National Institutes of Health	Characterizing the Role of ER-Shaping Proteins during RNA Virus Infection	\$27,885.00	\$0.00	\$27,885.00	01-Mar-17	31-Jul-17
Infectious Diseases	Lin, Philana Ling	National Institutes of Health	HIV-TB Co-Infection: Tracking TB Emergence after Asymptomatic (Latent) Infection	\$471,766.00	\$204,989.00	\$676,755.00	15-Mar-14	28-Feb-19
Infectious Diseases	Lin, Philana Ling	National Institutes of Health	Host and Pathogen Diversity in Mtb and SIV Infection	\$123,275.00	\$66,568.00	\$189,843.00	01-Jul-16	30-Jun-18
Infectious Diseases	Williams, John	National Institutes of Health	Host Determinants of Human Metapneumovirus and Pathogenesis	\$255,816.00	\$124,777.00	\$380,593.00	02-Jun-16	31-May-21
Neonatology	Ghazi, Arjumand	National Institutes of Health	The Coordination of Lipid Synthesis and Breakdown in Metabolism and Aging	\$180,000.00	\$99,450.00	\$279,450.00	01-Aug-16	30-Apr-20
Neonatology	Ghazi, Arjumand	National Institutes of Health	The Coordination of Lipid Synthesis and Breakdown in Metabolism and Aging	\$206,641.00	\$101,359.00	\$308,000.00	01-Aug-16	30-Apr-20
Neonatology	Good, Misty	National Institutes of Health	Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis	\$14,836.00	\$1,116.00	\$15,952.00	05-Sep-14	30-Sep-16
Neonatology	Lamitina, Samuel T.	National Institutes of Health	Bipartite Regulation of Cellular Osmosensing in <i>C. elegans</i>	\$173,574.00	\$89,766.00	\$263,340.00	01-Jul-14	30-Nov-17
Neonatology	Lamitina, Samuel T.	National Institutes of Health	Mechanisms of C9orf72-Associated Dipeptide Toxicity	\$128,559.00	\$63,941.00	\$192,500.00	15-Aug-15	31-Jul-17
Neonatology	Lamitina, Samuel T.	National Institutes of Health	Modifiers of C9orf72-Associated Dipeptide Protein Toxicity in a <i>C. elegans</i> Model	\$112,614.00	\$54,796.00	\$167,410.00	01-Apr-16	31-Mar-18

NATIONAL INSTITUTES OF HEALTH (continued)

DIVISION	NAME	AGENCY TITLE	GRANT TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Nephrology	Airik, Rannar	National Institutes of Health	The Role of DNA Damage Response Signaling in Chronic Kidney Disease	\$161,137.00	\$83,234.00	\$244,371.00	01-Aug-15	31-Jul-18
Nephrology	Bates, Carl	National Institutes of Health	Critical Roles for Fibroblast Growth Factor Receptors in Bladder Development	\$225,000.00	\$121,500.00	\$346,500.00	01-Jul-15	30-Jun-19
Nephrology	Bates, Carl	National Institutes of Health	Research Training in Pediatric Nephrology	\$279,973.00	\$19,837.00	\$299,810.00	01-Jul-16	30-Jun-21
Nephrology	Ho, Jacqueline	National Institutes of Health	The Role of miR-17~92 in Nephron Progenitors	\$228,331.00	\$110,879.00	\$339,210.00	19-Sep-14	31-Aug-19
Nephrology	Maringer, Katherine	National Institutes of Health	The Role of Oxygen Tension in Regulating the Differentiation of Nephron Progenitors	\$60,618.00	\$0.00	\$60,618.00	01-Jan-17	31-Dec-18
Nephrology	Sims-Lucas, Sunder	National Institutes of Health	Renal Stroma-Derived Endothelial Precursors Are Critical for Renal Development	\$103,183.00	\$8,175.00	\$111,358.00	15-Jul-13	31-May-18
Nephrology	Sims-Lucas, Sunder	National Institutes of Health	Kidney-Derived Endothelial Progenitors Play a Critical Role during Kidney Injury	\$50,000.00	\$27,563.00	\$77,563.00	01-Apr-17	31-Mar-18
Nephrology	Swiatecka-Urban, Agnieszka	National Institutes of Health	Novel Pathways in TGF Beta Signaling	\$232,484.00	\$119,070.00	\$351,554.00	15-Sep-16	31-Aug-17
Neurology	Fyffe-Maricich, Sharyl	National Institutes of Health	The Role of ERK1/2 MAP Kinase Signaling in CNS Myelination	\$218,750.00	\$113,400.00	\$332,150.00	01-Jul-15	30-Jun-20
Neurology	Pandey, Udai	National Institutes of Health	Cellular and Molecular Mechanisms of FUS-Related Amyotrophic Lateral Sclerosis	\$0.00	\$0.00	\$0.00	01-Jan-17	28-Feb-18
Neurology	Pandey, Udai	National Institutes of Health	Cellular and Molecular Mechanisms of FUS-Related Amyotrophic Lateral Sclerosis	\$8,300.00	\$4,482.00	\$12,782.00	01-Jan-17	28-Feb-18
Neurology	Pandey, Udai	National Institutes of Health	Cellular and Molecular Mechanisms of FUS-Related Amyotrophic Lateral Sclerosis	\$249,267.00	\$137,089.00	\$386,356.00	01-Mar-14	28-Feb-18
Neurology	Pandey, Udai	National Institutes of Health	Molecular Mechanisms of C9orf72 and Matrin 3 Interaction in ALS	\$150,000.00	\$82,313.00	\$232,313.00	01-Feb-17	31-Jan-19
Pulmonology	Alcorn, John	National Institutes of Health	Influenza A Inhibits TH17 Host Defense against Bacterial Pneumonia	\$250,000.00	\$137,813.00	\$387,813.00	01-Apr-17	31-Mar-21
Pulmonology	Brehm, John	National Institutes of Health	Vitamin D, Genomics, and Asthma Morbidity in Puerto Rican Children	\$0.00	\$0.00	\$0.00	01-Aug-13	30-Jun-16
Pulmonology	Celedon, Juan C	National Institutes of Health	Pittsburgh Training Grant in Pediatric Pulmonary Medicine	\$141,325.00	\$9,819.00	\$151,144.00	01-Jul-16	30-Jun-21
Pulmonology	Celedon, Juan C	National Institutes of Health	Vitamin D to Prevent Severe Asthma Exacerbations in High-Risk Children	\$630,661.00	\$111,781.00	\$742,442.00	15-Jun-15	31-May-20
Pulmonology	Celedon, Juan C	National Institutes of Health	Epigenetic Variation and Childhood Asthma in Puerto Ricans	\$0.00	\$0.00	\$0.00	01-Aug-13	31-Oct-17
Pulmonology	Chen, Wei	National Institutes of Health	AMD Genetics: Methods and Analysis for Progression, Prediction, and Association	\$0.00	\$0.00	\$0.00	01-Apr-14	31-Mar-18
Pulmonology	Chen, Wei	National Institutes of Health	Statistical Methods for Population and Family-Based Whole-Genome Sequence Data	\$216,216.00	\$90,039.00	\$306,255.00	25-Apr-14	31-Jan-19
Pulmonology	Forno, Erick	National Institutes of Health	Obesity and Asthma Subphenotypes and Underlying Genetic and Genomic Pathways	\$139,339.00	\$10,987.00	\$150,326.00	01-Jul-15	30-Jun-19
Pulmonology	Wang, Jieru	National Institutes of Health	Regulation of Alveolar Epithelial Homeostasis in Acute Lung Injury	\$0.00	\$0.00	\$0.00	01-Mar-14	28-Feb-18
Richard King Mellon Foundation Institute	Canna, Scott	National Institutes of Health	Mechanisms of NLR4 Inflammasome-Associated Hyperinflammation	\$150,000.00	\$12,000.00	\$162,000.00	01-Mar-17	28-Feb-19
Richard King Mellon Foundation Institute	Hand, Timothy	National Institutes of Health	Basic and Translational Studies of Cystic Fibrosis	\$82,560.00	\$44,582.00	\$127,142.00	01-Jun-16	31-May-17
Richard King Mellon Foundation Institute	Hand, Timothy	National Institutes of Health	Regulation of Commensal-Specific T Cells during Gastrointestinal Inflammation	\$100,000.00	\$8,000.00	\$108,000.00	20-Aug-15	31-Jul-17

NATIONAL INSTITUTES OF HEALTH (continued)

DIVISION	NAME	AGENCY TITLE	GRANT TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Th17 Cytokines and Lung Immunity	\$288,539.00	\$152,312.00	\$440,851.00	01-Jan-15	31-Dec-19
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	T Cells and <i>P. carinii</i> Pneumonia	\$279,433.00	\$150,894.00	\$430,327.00	01-Feb-16	31-Jan-20
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Improved Therapeutics and Diagnostics for <i>Pneumocystis</i> Pneumonia	\$310,531.00	\$166,015.00	\$476,546.00	01-Feb-16	31-Jan-21
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Generation of Novel Human Monoclonals for Lung Disease	\$131,674.00	\$72,584.00	\$204,258.00	01-Apr-16	31-Mar-18
Weight Management and Wellness	Lee, SoJung	National Institutes of Health	Resistance and Cardiorespiratory Time-Matched Exercise Training in Youth: A Randomized, Controlled Trial	\$745,378.00	\$331,768.00	\$1,077,146.00	15-Aug-13	31-May-18

OTHER FEDERAL FUNDING

DIVISION	NAME	AGENCY TITLE	GRANT TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Adolescent Medicine	Miller, Elizabeth	Health Resources and Services Administration	Behavioral Health and Workforce Education and Training for Professionals	\$14,022.00	\$1,123.00	\$15,145.00	30-Sep-14	29-Sep-17
Adolescent Medicine	Miller, Elizabeth	Centers for Disease Control and Prevention	A Cluster-Randomized Trial of a Middle School Gender Violence Prevention Program	\$232,732.00	\$117,146.00	\$349,878.00	01-Sep-14	31-Aug-17
Adolescent Medicine	Miller, Elizabeth	Centers for Disease Control and Prevention	Engendering Healthy Masculinities to Prevent Sexual Violence	\$294,474.00	\$155,206.00	\$449,680.00	30-Sep-14	29-Sep-18
Child Development Unit	Noll, Robert	Health Resources and Services Administration	LEND Center of Pittsburgh	\$81,220.00	\$4,252.00	\$85,472.00	01-Jul-11	31-Dec-16
Endocrinology	Dong, Hengjiang	Pennsylvania Department of Health	Development of Anti-FoxO1 Small-Molecule Drugs for Diabetic Hyperlipidemia	\$70,833.00	\$14,167.00	\$85,000.00	01-Jan-17	31-Dec-20
Infectious Diseases	Lin, Philana Ling	Pennsylvania Department of Health	Blood Signature of Reactivation Tuberculosis Risk	\$54,847.00	\$10,969.00	\$65,816.00	01-Jan-17	31-Dec-20
Infectious Diseases	Williams, John	Centers for Disease Control and Prevention	New Vaccine Surveillance Network (Supplement)	\$509,377.00	\$276,338.00	\$785,715.00	01-Sep-16	31-Aug-17
Infectious Diseases	Williams, John	Centers for Disease Control and Prevention	New Vaccine Surveillance Network	\$150,682.00	\$63,603.00	\$214,285.00	01-Sep-16	31-Aug-21
Neurology	Asato, Miya	Department of Health and Human Services	LEND Center at the University of Pittsburgh	\$570,732.00	\$45,659.00	\$616,391.00	01-Jul-16	30-Jun-21
Neurology	Pandey, Udai	Pennsylvania Department of Health	Determining Pathogenic Mechanisms of Amyotrophic Lateral Sclerosis	\$70,834.00	\$14,166.00	\$85,000.00	01-Jan-17	31-Dec-20
Pulmonology	Alcorn, John	Pennsylvania Department of Health	The Role of IL-22 in Influenza, Bacterial Super-Infection	\$70,833.00	\$14,167.00	\$85,000.00	01-Jan-17	31-Dec-20
Rheumatology	Vallejo, Abbe	Pennsylvania Department of Health	Unraveling Innate Immunopathways of Healthy Longevity in a Mouse Model	\$70,831.00	\$14,166.00	\$84,997.00	01-Jan-17	31-Dec-20

FOUNDATIONS AND OTHER FUNDING

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	Predicting Suicide Risk in Sexual Minority and Nonminority Youth: Associations among Neural Sensitivity to Social Rejection, Peer Rejection, and Suicidality	\$4,103.00	\$328.00	\$4,431.00	01-Jun-17	31-May-18
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	Substance Use Disparities among Transgender Youth	\$11,458.00	\$6,216.00	\$17,674.00	15-Sep-15	31-Aug-17
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	Pittsburgh Girls Study: Substance Use and HIV Risk Behaviors/STI in Young Adulthood	\$10,313.00	\$5,569.00	\$15,882.00	01-Jul-16	30-Apr-21
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	Pittsburgh Girls Study: Substance Use and HIV Risk Behaviors/STI in Young Adulthood	\$11,661.00	\$6,443.00	\$18,104.00	01-Jul-16	30-Apr-21
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute, administrative budget	\$10,503.00	\$5,672.00	\$16,175.00	12-Jul-16	31-May-18
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute, administrative budget	\$11,670.00	\$6,462.00	\$18,132.00	12-Jul-16	31-May-18
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute, core budget	\$30,233.00	\$16,326.00	\$46,559.00	12-Jul-16	31-May-21
Adolescent Medicine	Miller, Elizabeth	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute, core budget	\$23,339.00	\$12,924.00	\$36,263.00	12-Jul-16	31-May-21
Adolescent Medicine	Miller, Elizabeth	Johns Hopkins University	The IPV Provider Network: Engaging the Health Care Provider Response to Interpersonal Violence Against Women	\$56,157.00	\$16,847.00	\$73,004.00	15-Aug-15	31-Jul-18
Adolescent Medicine	Miller, Elizabeth	Grable Foundation	Sisterhood 2.0	\$20,000.00	\$0.00	\$20,000.00	01-Jan-17	31-Dec-17
Adolescent Medicine	Miller, Elizabeth	American Academy of Pediatrics	Community-Pediatric Partnerships for Child Well-Being	\$17,500.00	\$0.00	\$17,500.00	01-Jul-15	14-Jan-17
Adolescent Medicine	Miller, Elizabeth	Blue Shield of California	Improving Systems of Care: Exploring Local-Level Impacts	\$20,970.00	\$2,950.00	\$23,920.00	01-Jan-16	30-Nov-17
Adolescent Medicine	Pulcini, Christian	American Academy of Pediatrics	Trauma-Informed Home Visitation for At-Risk Families	\$2,000.00	\$0.00	\$2,000.00	01-Sep-16	28-Feb-17
Allergy and Immunology	Chen, Wei	National Institutes of Health	Parameters That Underlie Treg Insufficiency in Autoimmune Diabetes	\$12,915.00	\$7,071.00	\$19,986.00	01-Jan-17	31-Dec-17
Allergy and Immunology	Chen, Wei	National Institutes of Health	Endogenous Alpha-to-Beta Cells Transdifferentiation in Diabetes	\$8,599.00	\$4,741.00	\$13,340.00	01-Apr-17	31-Mar-22
Allergy and Immunology	Green, Todd	Food Allergy Research and Education	FARE Clinical Center of Excellence FCN	\$109,091.00	\$10,909.00	\$120,000.00	01-Jul-15	30-Jun-17
Allergy and Immunology	Manni, Michelle L.	National Institutes of Health	Anti-Inflammatory Lipid Mediators in Asthma	\$9,285.00	\$5,014.00	\$14,299.00	05-Aug-16	30-Jun-17
Allergy and Immunology	Manni, Michelle L.	Parker B. Francis Foundation	The Role of IL-22Ra2 in Allergic Airway Disease	\$50,000.00	\$0.00	\$50,000.00	01-Jul-16	30-Jun-19
Bone Marrow Transplant/Cell Therapy	Byersdorfer, Craig	Hyundai Hope on Wheels	Metabolic Inhibition to Preserve Anti-Leukemia Responses while Minimizing GVHD	\$125,000.00	\$0.00	\$125,000.00	01-Jan-17	31-Dec-18
Bone Marrow Transplant/Cell Therapy	Szabolcs, Paul	National Institutes of Health	Dendritic Cell (Dcreg) Therapy in Live Donor Renal Transplant Recipients	\$4,583.00	\$2,481.00	\$7,064.00	15-Aug-16	31-Jul-17
Bone Marrow Transplant/Cell Therapy	Szabolcs, Paul	Emory University	Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease-Capitation Portion	\$0.00	\$0.00	\$0.00	01-Sep-15	31-Jul-17
Bone Marrow Transplant/Cell Therapy	Szabolcs, Paul	Emory University	Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease	\$22,488.00	\$12,171.00	\$34,659.00	01-Sep-15	31-Jul-17
Cardiology	Feingold, Brian	Wayne State University	Cardiac Biomarkers in Pediatric Cardiomyopathy	\$949.00	\$512.00	\$1,461.00	01-Apr-15	30-Jun-17

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Cardiology	Feingold, Brian	Vanderbilt University Medical Center	Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence	\$26,644.00	\$14,388.00	\$41,032.00	01-Feb-13	31-Jan-17
Cardiology	Feingold, Brian	New England Research Institute	Pediatric Health Network FUEL Trial	\$69,052.00	\$37,806.00	\$106,858.00	01-Jan-17	30-Jun-17
Child Advocacy Center	Berger, Rachel	National Institutes of Health	Validation of Serum Biomarkers to Classify Outcome after Pediatric Cardiac Arrest	\$3,563.00	\$1,924.00	\$5,487.00	01-Jun-16	31-May-21
Child Advocacy Center	Berger, Rachel	Pennsylvania Department of Public Welfare	Pennsylvania Child Welfare Training Program - IV-B Project	\$5,571.00	\$836.00	\$6,407.00	01-Jul-11	30-Jun-17
Child Advocacy Center	Berger, Rachel	Pennsylvania Department of Public Welfare	Pennsylvania Child Welfare Training Program - IV-B Project	\$12,999.00	\$1,950.00	\$14,949.00	01-Jul-11	30-Jun-17
Child Advocacy Center	Berger, Rachel	Patient-Centered Outcomes Research Institute	Using the EMR to Decrease Disparities in Screening for Child Physical Abuse	\$27,768.00	\$11,107.00	\$38,875.00	01-Sep-13	31-Aug-17
Child Advocacy Center	Berger, Rachel	Hillman Center	Decreasing Unsafe Sleep in Allegheny County: A Multidisciplinary, Multipronged Approach	\$181,819.00	\$18,181.00	\$200,000.00	01-Apr-16	31-Mar-18
Child Development Unit	Johnson, Cynthia	Autism Speaks	Autism Treatment Network 2014 Cycle	\$35,905.00	\$3,590.00	\$39,495.00	01-Sep-14	31-Aug-17
Child Development Unit	Noll, Robert	University of Rochester School of Medicine	Problem-Solving Skills Training for Clinicians Providing Psychosocial Care in Pediatric Oncology	\$70,646.00	\$5,652.00	\$76,298.00	01-Apr-15	31-Mar-20
Child Development Unit	Noll, Robert	Children's Research Institute	Neurocognitive Assessments within COG: An Intensive Model for Successfully Evaluating Children with High-Risk ALL	\$6,415.00	\$0.00	\$6,415.00	15-Dec-14	14-Dec-17
Cystic Fibrosis Research Center	Bertrand, Carol	National Institutes of Health	Building Multilevel Models of Therapeutic Response in the Lungs	\$17,035.00	\$9,199.00	\$26,234.00	01-Sep-16	30-Jun-17
Cystic Fibrosis Research Center	Bertrand, Carol	Cystic Fibrosis Foundation	Regulation of a Cystic Fibrosis Disease Modifier, SLC26A9	\$125,000.00	\$0.00	\$125,000.00	01-Mar-17	28-Feb-18
Cystic Fibrosis Research Center	Frizzell, Raymond	National Institutes of Health	Basic and Translational Studies of Cystic Fibrosis, operating account, Core A	\$291,177.00	\$157,236.00	\$448,413.00	01-Jul-16	31-May-17
Cystic Fibrosis Research Center	Frizzell, Raymond	National Institutes of Health	Basic and Translational Studies of Cystic Fibrosis, operating account, Core A	\$299,912.00	\$161,952.00	\$461,864.00	01-Jul-16	31-May-17
Cystic Fibrosis Research Center	Frizzell, Raymond	Cystic Fibrosis Foundation	Selective Steps in Wild-Type and F508del CFTR Processing	\$230,238.00	\$18,419.00	\$248,657.00	01-Sep-15	31-Aug-16
Cystic Fibrosis Research Center	Frizzell, Raymond	Cystic Fibrosis Foundation	PITT RDP Research and Development Program Component II	\$500,000.00	\$0.00	\$500,000.00	01-Jul-15	30-Jun-19
Emergency Medicine	Hickey, Robert	University of Virginia	Established Status Epilepticus Treatment Trial	\$649.00	\$351.00	\$1,000.00	01-Sep-14	28-Feb-18
Emergency Medicine	Hickey, Robert	University of Michigan	Emergency Department Screen for Teens at Risk for Suicide	\$107,840.00	\$58,234.00	\$166,074.00	01-Sep-14	30-Jun-17
Emergency Medicine	Hickey, Robert	University of Michigan	Supplement-Emergency Department Screen for Teens at Risk for Suicide	\$14,873.00	\$8,031.00	\$22,904.00	01-Jul-16	30-Jun-17
Emergency Medicine	Hickey, Robert	Centers for Disease Control and Prevention	Outpatient VE for Seasonal Flu, Pandemic Flu, and RSV in a Large, Diverse Network	\$42,976.00	\$23,261.00	\$66,237.00	01-Aug-16	31-Jul-21
Emergency Medicine	Hickey, Robert	Nationwide Children's Hospital	Great Lakes Emergency Medical Services for Children Research Network	\$86,409.00	\$25,923.00	\$112,332.00	01-Sep-16	31-Aug-19
Emergency Medicine	Manole, Mioara	National Institutes of Health	Mitochondria-Targeted Redox Therapy for Cerebral Ischemia in the Developing Brain	\$4,706.00	\$2,541.00	\$7,247.00	15-Mar-14	31-Dec-18
Endocrinology	Arsanian, Silva	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute	\$78,303.00	\$42,284.00	\$120,587.00	01-Jul-11	30-Jun-18
Endocrinology	Arsanian, Silva	George Washington University	Treatment Options for Type 2 Diabetes in Adolescents and Youth TODAY2 PHASE 2 (T2P2) Long-Term Post-Intervention Follow-Up Protocol	\$155,898.00	\$79,951.00	\$235,849.00	01-Aug-15	30-Apr-20

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Endocrinology	Arslanian, Silva	George Washington University	TODAY2 Phase 2 (T2P2): Long-Term Post-Intervention Follow-Up	\$194,009.00	\$107,190.00	\$301,199.00	01-May-16	30-Apr-21
Endocrinology	Arslanian, Silva	University of Colorado Denver	Brief Intensive Glycemic Control and Beta Cell Function in Pediatric Type 2 Diabetes	\$280,735.00	\$133,915.00	\$414,650.00	24-Sep-11	30-Jun-17
Endocrinology	Becker, Dorothy	University of South Florida	Diabetes Prevention Trial Supplement	\$86,863.00	\$0.00	\$86,863.00	17-Apr-09	06-Feb-18
Endocrinology	Becker, Dorothy	Carnegie Mellon University	From Adolescence to Adulthood: Persons with and without Diabetes	\$55,412.00	\$28,537.00	\$83,949.00	01-Jul-12	30-Jun-17
Endocrinology	Becker, Dorothy	University of South Florida	The Environmental Determinants of Diabetes in the Young	\$3,585.00	\$1,936.00	\$5,521.00	01-Sep-13	30-Jun-17
Endocrinology	Becker, Dorothy	University of South Florida	Clinic Affiliate Prediction and Prevention 1 Diabetes (TrialNet)	\$72,727.00	\$39,273.00	\$112,000.00	23-Mar-15	30-Jun-17
Endocrinology	Becker, Dorothy	University of Bristol	What Protects Islet Autoantibody-Positive T1D Relatives Who Do Not Progress?	\$18,940.00	\$1,894.00	\$20,834.00	01-Apr-15	31-Aug-17
Endocrinology	Dong, Hengjiang	American Diabetes Association	Hepatic Insulin for Diabetes	\$104,545.00	\$10,455.00	\$115,000.00	01-Jan-17	31-Dec-19
Endocrinology	Witchel, Selma	National Institutes of Health	Substance Use Disparities Among Transgender Youth	\$8,973.00	\$4,868.00	\$13,841.00	15-Sep-15	31-Aug-17
Endocrinology	Witchel, Selma	American Academy of Pediatrics	Persistent Symptoms of Hyperandrogenism in Girls with a History of Premature Adrenarche or Adolescent Hyperandrogenism	\$0.00	\$0.00	\$0.00	01-Aug-15	31-May-17
Gastroenterology	Keljo, David	Cornell University, Weill Cornell Medicine	Sex Differences in Statural Growth Impairment in Pediatric Crohn's Disease	\$14,719.00	\$3,798.00	\$18,517.00	01-Sep-16	30-Apr-19
Gastroenterology	Keljo, David	Cornell University, Weill Cornell Medicine	Sex Differences in Statural Growth Impairment in Pediatric Crohn's Disease	\$9,875.00	\$5,333.00	\$15,208.00	01-Sep-16	30-Apr-19
Gastroenterology	Keljo, David	Cornell University, Weill Cornell Medicine	Sex Differences in Statural Growth Impairment in Pediatric Crohn's Disease, Per Patient	\$7,957.00	\$0.00	\$7,957.00	01-Sep-16	30-Apr-17
Gastroenterology	Keljo, David	Emory University	Risk Stratification and Identification of Immunogenetic and Microbial Markers of Complicated Disease Course in Pediatric Crohn's Disease	\$7,636.00	\$764.00	\$8,400.00	01-Jul-16	30-Jun-17
Gastroenterology	Keljo, David	Mount Sinai School of Medicine	A Multidisciplinary Human Study on the Genetic, Environmental, and Microbial Interactions That Cause IBC	\$0.00	\$0.00	\$0.00	01-Sep-14	30-Sep-17
Gastroenterology	Keljo, David	Mount Sinai School of Medicine	A Multidisciplinary Human Study on the Genetic, Environmental, and Microbial Interactions That Cause IBD (GEM Project) Per Patient	\$0.00	\$0.00	\$0.00	01-Sep-14	30-Sep-17
Gastroenterology	Khan, Zahida	Alpha-1 Foundation	Advanced Single-Cell Analysis of Proliferation in PIZ Mouse Hepatocytes	\$40,000.00	\$0.00	\$40,000.00	01-Jul-16	30-Jun-17
Gastroenterology	Lowe, Mark	National Institutes of Health	Consortium for the Study of Pancreatitis: Pittsburgh Clinical Center	\$4,583.00	\$2,486.00	\$7,069.00	01-Sep-15	31-Mar-17
Gastroenterology	Siebold, Leah	Hospital for Sick Children	NEOPICS-Intestinal Disease Biobank: Genetic, Functional, and Microbial Studies in Intestinal Disease	\$9,091.00	\$909.00	\$10,000.00	01-Oct-14	30-Sep-17
Gastroenterology	Siebold, Leah	Hospital for Sick Children	Defining Very Early Onset IBD	\$1,500.00	\$150.00	\$1,650.00	01-Sep-16	28-Feb-17
Gastroenterology	Squires, James	National Institutes of Health	Creating Models of Rare Childhood Liver Diseases Using the Human Liver-on-a-Chip	\$2,101.00	\$1,134.00	\$3,235.00	01-Jul-16	30-Jun-17
Gastroenterology	Squires, James	Pittsburgh Liver Research Center	Pilot and Feasibility Grant	\$25,000.00	\$0.00	\$25,000.00	01-Sep-16	31-Aug-17
Gastroenterology	Squires, Robert	National Institutes of Health	Hepatitis B Clinical Research Network, Data Coordinating Center	\$11,670.00	\$6,302.00	\$17,972.00	01-Sep-15	31-May-20
Gastroenterology	Venkat, Veena	University of California San Francisco	Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients	\$1,084.00	\$558.00	\$1,642.00	01-Jul-14	30-Jun-17

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Gastroenterology	Xiao, Xunjun	National Pancreas Foundation	CEL-HYB Confer Susceptibility to Chronic Pancreatitis through Proteotoxicity	\$537.00	\$0.00	\$537.00	01-Jul-16	31-Mar-17
General Academic Pediatrics	Bogen, Debra	National Institutes of Health	Factors Contributing to Oral Health Disparities in Appalachia	\$4,802.00	\$2,593.00	\$7,395.00	01-Jul-16	30-Jun-21
General Academic Pediatrics	Bogen, Debra	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute	\$63,431.00	\$34,253.00	\$97,684.00	12-Jul-16	31-May-21
General Academic Pediatrics	Bogen, Debra	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute	\$73,901.00	\$40,923.00	\$114,824.00	12-Jul-16	31-May-21
General Academic Pediatrics	Bogen, Debra	Tufts Medical Center, Inc.	Improving Outcomes in Neonatal Abstinence Syndrome	\$12,870.00	\$6,950.00	\$19,820.00	01-Oct-14	30-Jun-17
General Academic Pediatrics	Bogen, Debra	University of Massachusetts Worcester	Stochastic Vibro-Tactile Stimulation: A Non-Pharmacological Intervention for Abstinence and Drug Withdrawal in Newborn Infants	\$137,948.00	\$74,493.00	\$212,441.00	01-Aug-16	30-Jun-21
General Academic Pediatrics	Bogen, Debra	Magee-Womens Research Institute and Foundation	A Phase 1 Pharmacokinetic Trial of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination in Pregnant Women with Chronic Hepatitis C Infections	\$9,667.00	\$5,244.00	\$14,911.00	21-Sep-16	31-Aug-17
General Academic Pediatrics	Bogen, Debra	National Science Foundation	Optimal Management of Donor Milk Banks	\$3,953.00	\$2,135.00	\$6,088.00	01-Sep-15	31-Aug-18
General Academic Pediatrics	Bogen, Debra	RAND Corporation	Expanding Rural Access to Breastfeeding Support: A Pilot RCT	\$45,176.00	\$24,904.00	\$70,080.00	01-Apr-16	31-Mar-19
General Academic Pediatrics	Bogen, Debra	Magee-Womens Research Institute and Foundation	A Phase 1 Pharmacokinetic Trial of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Pregnant Women with Chronic Hepatitis C Virus Infection	\$14,750.00	\$2,452.00	\$17,202.00	01-Aug-16	31-Jul-17
General Academic Pediatrics	Hoberman, Alejandro	Ricoh Innovations Corporation	Acquisition and Classification of Light-field Data of the Tympanic Membrane™ and Middle Ear Processes of Children Suspected of Having Otitis Media	\$202,230.00	\$124,371.00	\$326,601.00	28-Mar-14	31-Mar-17
General Academic Pediatrics	Malinow, Ana	American Academy of Pediatrics	Making it to the Doctor	\$10,000.00	\$0.00	\$10,000.00	01-Sep-16	31-Aug-17
General Academic Pediatrics	Martin, Judith	Centers for Disease Control and Prevention	Outpatient VE for Seasonal Flu, Pandemic Flu, and RSV in a Large, Diverse Network (CORE-VE)	\$50,043.00	\$27,086.00	\$77,129.00	01-Aug-16	31-Jul-17
General Academic Pediatrics	Martin, Judith	Vanderbilt University	Vaccine and Treatment Evaluation Units, Task Area B-C Task Order 14-0079. B1C1.0028	\$118,334.00	\$63,899.00	\$182,233.00	01-Sep-15	31-Jul-18
General Academic Pediatrics	Ray, Kristin	Harvard Medical School	Evaluation of the Los Angeles Department of Health Services eConsult Program Project	\$8,143.00	\$1,222.00	\$9,365.00	01-Oct-16	30-Sep-18
General Academic Pediatrics	Reis, Evelyn	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute	\$10,521.00	\$5,681.00	\$16,202.00	12-Jul-16	31-May-21
General Academic Pediatrics	Reis, Evelyn	National Institutes of Health	University of Pittsburgh Clinical and Translational Science Institute	\$11,233.00	\$6,220.00	\$17,453.00	12-Jul-16	31-May-21
General Academic Pediatrics	Reis, Evelyn	Centers for Disease Control and Prevention	Outpatient VE for Seasonal Flu, Pandemic Flu, and RSV in a Large, Diverse Network	\$7,671.00	\$4,152.00	\$11,823.00	01-Aug-16	31-Jul-21
General Academic Pediatrics	Shope, Timothy	American Academy of Pediatrics	Improving the Pediatric Community's Readiness and Response to Seasonal and Pandemic Influenza	\$14,286.00	\$7,714.00	\$22,000.00	01-Nov-14	30-Jun-17
Genetics	Madan-Khetarpal, Suneeta	National Institutes of Health	Genetics of Extracellular Matrix in Health and Disease	\$25,068.00	\$13,787.00	\$38,855.00	01-Apr-15	31-Mar-20
Genetics	Nicholls, Robert	Spastic Paraplegia Foundation, Inc.	Gene Co-Regulation in the Hereditary Spastic Paraplegias	\$0.00	\$0.00	\$0.00	01-Oct-10	31-Dec-17
Genetics	Nicholls, Robert	Foundation for Prader-Willi Research	Activation of Silenced Genes in Prader-Willi Syndrome	\$0.00	\$0.00	\$0.00	01-Sep-15	30-Jun-17
Genetics	Nicholls, Robert	Foundation for Prader-Willi Research	Activation of Silenced Genes in Prader-Willi Syndrome	\$0.00	\$0.00	\$0.00	01-Sep-15	30-Jun-17

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Genetics	Nicholls, Robert	Foundation for Prader-Willi Research	Understanding Multiple Hormone Secretion Deficits in Prader-Willi Syndrome	\$100,000.00	\$8,000.00	\$108,000.00	01-Oct-16	30-Sep-17
Genetics	Vockley, Gerard	National Institutes of Health	Pre-Clinical Studies of Novel Mitochondrial Gene Therapies	\$5,156.00	\$2,784.00	\$7,940.00	01-Apr-15	31-Jan-19
Genetics	Vockley, Gerard	Baebies, Incorporated	Point-of-Birth Newborn Screening for Inborn Errors of Metabolism Using Digital Microfluidic Technology	\$22,525.00	\$12,219.00	\$34,744.00	16-Sep-16	31-Aug-18
Genetics	Vockley, Gerard	Nebraska Medical Center	Sterol and Isoprenoid Diseases Consortium	\$2,152.00	\$1,162.00	\$3,314.00	04-Sep-14	31-Aug-19
Hematology/ Oncology	Bailey, Kelly	Alex's Lemonade Stand	Micro-Environmental Regulators of Ewing Sarcoma Metastasis	\$51,000.00	\$0.00	\$51,000.00	01-Oct-16	30-Sep-19
Hematology/ Oncology	Cohen, Debra	Emory University	Patient-Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease-Modifying Therapy with Hydroxyurea in Patients with Sickle Cell Disease	\$48,862.00	\$19,544.00	\$68,406.00	01-Jul-14	31-Jan-17
Hematology/ Oncology	Cooper, James	All Children's Research Institute, Inc.	Prospective Evaluation of the Duration of Therapy for Thrombosis in Children Study	\$6,310.00	\$1,893.00	\$8,203.00	11-Jan-17	30-Jun-17
Hematology/ Oncology	Cooper, James	All Children's Research Institute, Inc.	Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children	\$8,166.00	\$0.00	\$8,166.00	01-May-14	31-Dec-18
Hematology/ Oncology	Goyal, Rakesh	Children's Hospital of Philadelphia	Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies	\$9,399.00	\$5,044.00	\$14,443.00	01-Jul-14	30-Jun-17
Hematology/ Oncology	Hillery, Cheryl	Medical College of Wisconsin	Mechanisms of Inflammation in Sickle Cell Disease	\$50,000.00	\$27,000.00	\$77,000.00	01-Apr-16	31-Mar-21
Hematology/ Oncology	Lucas, Peter	U.S. Army	Transcriptomic Profiling and Functional Characterization of Fusion Genes in Recurrent Ovarian Cancer (OC150095)	\$12,380.00	\$6,709.00	\$19,089.00	15-Aug-16	14-Aug-18
Hematology/ Oncology	Lucas, Peter	Breast Cancer Research Foundation	Intra-Tumor Heterogeneity (ITH) in Primary and Metastatic Breast Cancer	\$12,650.00	\$2,530.00	\$15,180.00	01-Oct-15	30-Sep-17
Hematology/ Oncology	Lucas, Peter	Breast Cancer Research Foundation	Endocrine-Resistant Invasive Lobular Breast Cancer	\$12,650.00	\$2,530.00	\$15,180.00	01-Oct-16	30-Sep-17
Hematology/ Oncology	Maurer, Scott	National Institutes of Health	Peptide Vaccine Immunotherapy for Children with Recurrent Low-Grade Astrocytomas	\$44,672.00	\$24,121.00	\$68,793.00	08-Jan-16	31-Dec-17
Hematology/ Oncology	Prochownik, Edward	Washington University	Project 1: Preclinical and Clinical Imaging and Treatment of Multiple Myeloma with cMyc-Max Nanoparticles	\$49,263.00	\$26,602.00	\$75,865.00	01-Sep-15	31-Jul-20
Hematology/ Oncology	Ritchey, Kim	Children's Hospital of Philadelphia	AALL1122 BMS CA180-372: A Phase 2, Multicenter, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	\$1,667.00	\$333.00	\$2,000.00	21-Jun-12	30-Jun-17
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	Children's Oncology Group Phase 1/ Pilot Consortium Grant	\$22,728.00	\$12,272.00	\$35,000.00	01-Aug-16	31-Jul-17
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	Per Case Reimbursement NIH National Clinical Trials Network BQSFP Grant U10CA180886-02S7-COG AALL0932	\$5,826.00	\$3,175.00	\$9,001.00	01-Mar-16	28-Feb-18
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	CHOP/COG-NIH-NCTN-Per Case Reimbursement AALL1131	\$19,252.00	\$10,589.00	\$29,841.00	01-Mar-16	28-Feb-18
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	Per Case Children's Oncology Group Phase I	\$25,000.00	\$5,000.00	\$30,000.00	01-Aug-10	31-Jul-17
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	COG NCORP Research Base, Per Case Reimbursement	\$20,779.00	\$11,221.00	\$32,000.00	01-Aug-14	31-Jul-19

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	ALTE1621 Reducing Risk of Anthracycline-Related Heart Failure after Childhood Cancer	\$14,529.00	\$7,937.00	\$22,466.00	01-Dec-16	30-Nov-21
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	CHOP/COG Chairs Grant Workload Intensity CA 180886	\$36,472.00	\$19,695.00	\$56,167.00	11-Apr-14	28-Feb-19
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	CHOP/COG NIH National Clinical Trials Network Per Case Reimbursement Grant CA 180886 Successor to COG Chairs Grant CA 98543	\$51,949.00	\$28,051.00	\$80,000.00	01-Mar-14	28-Feb-18
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	EVERYCHILD (APEC14B1) COG Foundation	\$30,000.00	\$0.00	\$30,000.00	26-Oct-15	25-Oct-20
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	Cancer Trials Support Unit (CTSU) Phase II Supplemental Payments (N01-CM-62212)	\$11,688.00	\$6,312.00	\$18,000.00	01-Jul-14	30-Jun-17
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	St. Baldrick's Foundation Supplemental Reimbursement	\$0.00	\$0.00	\$0.00	26-Apr-12	25-Apr-18
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	ADVL1315-Pfizer, Inc. No. W1181667: A Phase I Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA) in Children with Relapsed/Refractory Solid Tumors	\$13,600.00	\$3,400.00	\$17,000.00	29-Apr-15	28-Apr-18
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	A Phase 3 Randomized Trial for Newly Diagnosed High-Risk B-Precursor Acute Lymphoblastic Leukemia Testing Clofarabine (IND#73789, NSC#606869) in the Very High Risk Stratum	\$22,889.00	\$5,722.00	\$28,611.00	04-May-15	03-May-20
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	ADVL0912 Pfizer Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma	\$5,480.00	\$1,370.00	\$6,850.00	05-May-15	04-May-18
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	ADVL1212: A Phase 1 Study of Crizotinib (IND #105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	\$665.00	\$166.00	\$831.00	22-Jul-15	04-May-18
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	ADVL114: A Phase 1 Study of Eribulin Mesylate (E7389, IND#116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lymphomas	\$5,500.00	\$1,375.00	\$6,875.00	22-Jul-15	04-May-18
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	A Phase III, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic	\$18,217.00	\$4,554.00	\$22,771.00	17-Sep-15	16-Sep-20
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	AAML 1522:CC-5013-AML-002: A Phase 2, Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety, and Pharmacokinetics of Lenalidomide (Revlimid) in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia	\$6,815.00	\$1,704.00	\$8,519.00	25-Feb-16	24-Feb-21
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	ADVL1412: A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab	\$20,965.00	\$5,241.00	\$26,206.00	03-Mar-16	02-Mar-19
Hematology/Oncology	Tersak, Jean	Children's Hospital of Philadelphia	ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors	\$15,680.00	\$4,000.00	\$19,680.00	19-Apr-16	18-Apr-19

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents: A Groupwide Phase III Study	\$2,560.00	\$640.00	\$3,200.00	25-Aug-16	24-Aug-18
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	ADVL1621: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or PD-L1-Positive Advanced, Relapsed, or Refractory Solid Tumor or Lymphoma (Keynote-051) MK-3475-051	\$35,702.00	\$8,925.00	\$44,627.00	01-Nov-16	31-Oct-21
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)	\$12,966.00	\$3,241.00	\$16,207.00	06-Dec-16	31-Oct-21
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	COG AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with <i>De Novo</i> High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia	\$16,765.00	\$4,191.00	\$20,956.00	01-Mar-17	31-Jan-22
Hematology/ Oncology	Tersak, Jean	Children's Hospital of Philadelphia	AAML1031: A Phase III Randomized Trial for Patients with <i>De Novo</i> AML Using Bortezomib and Sorafenib (IND#11480:NSC#681239,NSC#74772) for Patients with High Allelic Ratio FLT3/ITD	\$5,807.00	\$1,452.00	\$7,259.00	01-Mar-17	31-Jan-22
Hematology/ Oncology	Tersak, Jean	Alex's Lemonade Stand	Children's Hospital of Pittsburgh of UPMC Phase 1-2 Infrastructure Support Grant Reapplication	\$125,000.00	\$0.00	\$125,000.00	01-Jan-14	31-Dec-18
Infectious Diseases	Coyne, Carolyn	National Institutes of Health	Exosome-Based Placental Maternal Communication	\$12,977.00	\$7,121.00	\$20,098.00	01-Feb-17	31-Jan-18
Infectious Diseases	Coyne, Carolyn	Magee-Womens Research Institute and Foundation	Primary Human Trophoblasts and the Transfer of Viral Resistance	\$26,077.00	\$13,430.00	\$39,507.00	01-Mar-17	31-May-17
Infectious Diseases	Dermody, Terence	Burroughs Wellcome Fund	2017 International Congress of Virology (ICV)	\$15,000.00	\$0.00	\$15,000.00	01-Mar-17	31-Oct-17
Infectious Diseases	Green, Michael	Duke University	Multicenter Studies to Improve Diagnosis and Treatment of Pediatric Candidiasis	\$1,085.00	\$585.00	\$1,670.00	01-Jun-15	31-May-18
Infectious Diseases	Green, Michael	Duke University	Multicenter Study to Improve Diagnosis and Treatment of Pediatric Candidiasis, Biopic Study	\$542.00	\$293.00	\$835.00	01-Jun-15	31-May-18
Infectious Diseases	Green, Michael	University of South Florida	NIDDK Type 1 Diabetes TrialNet Data Coordinating Center	\$0.00	\$0.00	\$0.00	01-Jan-15	28-Feb-18
Infectious Diseases	Green, Michael	University of South Florida	NIDDK Type 1 Diabetes TrialNet Data Coordinating Center	\$5,865.00	\$3,167.00	\$9,032.00	01-Jan-15	28-Feb-18
Infectious Diseases	Lin, Philana Ling	National Institutes of Health	Predicting Immune Responses That Correlate with Protection against Tuberculosis	\$24,567.00	\$13,266.00	\$37,833.00	01-Aug-12	30-Jun-17
Infectious Diseases	Lin, Philana Ling	National Institutes of Health	PET Probes Targeting Immune Cells for Imaging Tuberculosis	\$8,189.00	\$4,422.00	\$12,611.00	01-Jul-15	30-Jun-20
Infectious Diseases	Lin, Philana Ling	National Institutes of Health	The Consequences of Reinfection with <i>M. tuberculosis</i>	\$16,378.00	\$8,844.00	\$25,222.00	01-Jul-15	31-Dec-19
Infectious Diseases	Lin, Philana Ling	National Institutes of Health	An Adjuvant That Promotes TH1/TH17 and CD8 T Cells in a Tuberculosis Vaccine	\$16,179.00	\$8,737.00	\$24,916.00	01-Feb-13	31-Jan-18
Infectious Diseases	Lin, Philana Ling	National Institutes of Health	The Effects of <i>M. tuberculosis</i> Infection on Lung Microbiome in Macaques	\$3,263.00	\$1,795.00	\$5,058.00	01-Mar-16	28-Feb-18
Infectious Diseases	Lin, Philana Ling	National Institutes of Health	Rational Design of Combination Regimens Targeting Both Host and Pathogen	\$16,298.00	\$8,842.00	\$25,140.00	25-Sep-15	31-Aug-17

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Infectious Diseases	Lin, Philana Ling	University of Michigan	Predicting Protective T-Cell Responses in Tuberculosis Using a Biology Approach	\$2,750.00	\$1,485.00	\$4,235.00	01-Oct-16	31-Jan-18
Infectious Diseases	Lin, Philana Ling	University of Michigan	Predicting Protective T-Cell Responses in Tuberculosis Using a Biology Approach	\$8,232.00	\$4,445.00	\$12,677.00	01-Oct-16	31-Jan-18
Infectious Diseases	Lin, Philana Ling	Baylor College of Medicine	Surveillance of Invasive Pneumococcal Isolates after Pneumococcal Vaccination	\$9,600.00	\$2,400.00	\$12,000.00	18-Jun-15	17-Jun-18
Infectious Diseases	Lin, Philana Ling	Harvard School of Public Health	Immune Signatures of Differential NHP Granuloma States	\$17,343.00	\$1,734.00	\$19,077.00	01-Jan-16	30-Dec-17
Infectious Diseases	Lin, Philana Ling	Aeras Global TB Vaccine Foundation	Efficacy of BCG Administrated by Different Routes in the Rhesus Macaque Model of TB	\$16,450.00	\$1,645.00	\$18,095.00	06-Dec-16	30-Nov-17
Infectious Diseases	Michaels, Marian	Children's Hospital of Philadelphia	BAA: A Multicenter Prospective Study of Human Adenovirus Infection and Disease in Pediatric Human Stem Cell Transplant Recipients	\$76,297.00	\$42,510.00	\$118,807.00	01-Jul-16	30-Jun-21
Infectious Diseases	Michaels, Marian	University of Alabama	A Pharmacokinetic, Pharmacodynamic, and Resistance Evaluation of Intravenous Ganciclovir in Premature Infants	\$15,102.00	\$2,946.00	\$18,048.00	01-Feb-12	27-Sep-17
Infectious Diseases	Michaels, Marian	Duke University	Prospective Observational Study of the Risk Factors for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia	\$27,695.00	\$14,955.00	\$42,650.00	08-Dec-16	28-Mar-17
Infectious Diseases	Nowalk, Andrew John	National Institutes of Health	Colistin-Resistant <i>Acinetobacter baumannii</i>	\$3,175.00	\$1,715.00	\$4,890.00	15-Mar-14	28-Feb-18
Infectious Diseases	Williams, John	Centers for Disease Control and Prevention	Optional Component: Flu Vaccine Effectiveness in Those Hospitalized in a Large Diverse Health System	\$4,412.00	\$2,382.00	\$6,794.00	01-Aug-16	31-Jul-18
Infectious Diseases	Williams, John	Centers for Disease Control and Prevention	Flu Vaccine Effectiveness in Those Hospitalized in a Large Diverse Health System	\$18,529.00	\$10,006.00	\$28,535.00	01-Aug-16	31-Jul-18
Infectious Diseases	Williams, John	Centers for Disease Control and Prevention	Outpatient VE for Seasonal Flu, Pandemic Flu, and RSV in a Large, Diverse Network	\$63,993.00	\$34,636.00	\$98,629.00	01-Aug-16	31-Jul-21
Neonatology	Ghazi, Arjumand	Ellison Medical Foundation	miRNAs and Lipophilic Pathways That Transmit Reproductive Signals to Control Aging	\$0.00	\$0.00	\$0.00	01-Jul-12	31-Dec-16
Neonatology	Ghazi, Arjumand	Aging Institute of UPMC Senior Services and the University of Pittsburgh	Suppression of Age-Related Germline Tumorigenesis by Mitochondria-Targeted ROS Modulators	\$20,000.00	\$0.00	\$20,000.00	01-Feb-16	31-Jan-18
Neonatology	Lamitina, Samuel T.	United States-Israel Binational Science Foundation	Biomechanical Profiling of <i>C. elegans</i> motility	\$7,794.00	\$0.00	\$7,794.00	01-Oct-14	30-Sep-17
Neonatology	Silverman, Gary	National Institutes of Health	New Therapies for Liver Fibrosis, Project 2	\$0.00	\$0.00	\$0.00	24-Sep-12	31-Aug-17
Neonatology	Yanowitz, Toby Debra	University of California San Francisco	High-Dose Erythropoietin for Asphyxia and Encephalopathy	\$38,021.00	\$20,674.00	\$58,695.00	30-Sep-16	30-Jun-21
Neonatology	Yanowitz, Toby Debra	UPMC Enterprises	A Non-Invasive Diagnostic Test for Necrotizing Enterocolitis	\$6,222.00	\$3,827.00	\$10,049.00	01-Sep-16	31-May-17
Nephrology	Airik, Rannar	National Institutes of Health	Pittsburgh Center for Kidney Research	\$30,000.00	\$16,200.00	\$46,200.00	01-Aug-16	31-Jul-18
Nephrology	Bates, Carl	National Institutes of Health	Pittsburgh Center for Kidney Research, Core C	\$15,000.00	\$8,100.00	\$23,100.00	01-Aug-13	31-Jul-18
Nephrology	Bates, Carl	March of Dimes	17th Congress of the International Pediatric Nephrology Association	\$5,000.00	\$0.00	\$5,000.00	01-Jul-16	30-Jun-17
Nephrology	Ho, Jacqueline	National Institutes of Health	Role of MicroRNAs in Kidney Sodium Regulation	\$8,350.00	\$4,509.00	\$12,859.00	01-May-15	30-Apr-20
Nephrology	Ho, Jacqueline	National Institutes of Health	University of Pittsburgh as the GUDMAP Tissue Hub and Collection Site	\$25,912.00	\$13,992.00	\$39,904.00	15-Sep-16	31-May-21

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Nephrology	Ho, Jacqueline	National Institutes of Health	University of Pittsburgh as the GUDMAP Tissue Hub and Collection Site	\$36,506.00	\$20,220.00	\$56,726.00	15-Sep-16	31-May-21
Nephrology	Miyashita, Yosuke	Emory University	Cystinosis: Clinical Outcomes in a Contemporary Group of American Patients	\$3,714.00	\$2,286.00	\$6,000.00	25-Oct-16	24-Oct-17
Nephrology	Nguyen, Christina	McGill University	Teen Adherence in Kidney Transplant: Improving Tracking to Optimize Outcomes	\$3,611.00	\$1,950.00	\$5,561.00	01-Sep-16	30-Jun-21
Nephrology	Phua, Yu Leng	American Society of Nephrology Foundation	The Role of miR-17-92 in Nephron Progenitor Self-Renewal	\$50,000.00	\$0.00	\$50,000.00	01-Jul-15	30-Jun-17
Nephrology	Santos, Deborah	University of Michigan	The Role of the miR-17-92 MicroRNA Cluster in Glomerulopathies	\$28,935.00	\$2,315.00	\$31,250.00	01-Jan-17	31-Dec-17
Nephrology	Sims-Lucas, Sunder	National Institutes of Health	Effect of Aging on Urothelial Function	\$19,480.00	\$10,520.00	\$30,000.00	30-Sep-15	31-Aug-20
Nephrology	Sims-Lucas, Sunder	National Institutes of Health	University of Pittsburgh as the GUDMAP Tissue Hub and Collection Site	\$114,089.00	\$61,607.00	\$175,696.00	15-Sep-16	31-May-21
Nephrology	Sims-Lucas, Sunder	National Institutes of Health	University of Pittsburgh as the GUDMAP Tissue Hub and Collection Site	\$103,494.00	\$57,305.00	\$160,799.00	15-Sep-16	31-May-21
Nephrology	Swiatecka-Urban, Agnieszka	National Institutes of Health	Basis and Clinical Studies of Cystic Fibrosis	\$0.00	\$0.00	\$0.00	01-Jul-15	31-May-16
Nephrology	Swiatecka-Urban, Agnieszka	University of Pennsylvania	Primary Outcomes in Glomerulonephritis Study	\$4,137.00	\$1,720.00	\$5,857.00	01-Jun-14	31-May-18
Nephrology	Swiatecka-Urban, Agnieszka	American Heart Association	Lemur Tyrosine Kinase and TGF Beta Signaling	\$70,000.00	\$7,000.00	\$77,000.00	01-Jul-15	30-Jun-17
Neurology	Abdel-Hamid, Hoda	National Institutes of Health	Network of Excellence In Neuroscience Clinical Trials (University of Pittsburgh CRS)	\$3,188.00	\$1,642.00	\$4,830.00	30-Sep-11	30-Jun-18
Neurology	Asato, Miya	Autism Speaks Network	Autism Speaks Network	\$5,662.00	\$566.00	\$6,228.00	01-Sep-14	31-Aug-17
Neurology	Cummings, Dana	National Institutes of Health	Stroke Trials Network, Regional Coordinating Stroke Center	\$3,283.00	\$1,773.00	\$5,056.00	30-Sep-13	31-Jul-17
Neurology	Escolar, Maria	PPD Investigator Services, LLC	Natural History of Metachromatic Leukodystrophy and the Assessment of Disease Progression in Untreated and Hematopoietic Stem Cell Therapy-Treated Patients	\$2,000.00	\$1,230.00	\$3,230.00	01-Jul-16	30-Jun-17
Neurology	Escolar, Maria	Legacy of Angels Foundation	NDRD Krabbe Disease Patient Care and Research	\$347,773.00	\$17,389.00	\$365,162.00	01-Oct-15	30-Sep-18
Neurology	Escolar, Maria	Legacy of Angels Foundation	Development Program for the Treatment of Krabbe Disease Using Intravenous Adeno-Associated Virus Gene Therapy	\$544,491.00	\$11,314.00	\$555,805.00	01-Oct-15	30-Sep-18
Neurology	Escolar, Maria	Legacy of Angels Foundation	Treatment of Krabbe Disease Using Gene Therapy: Rat Toxicology Studies and Pre-Clinical Drug Production	\$1,965,567.00	\$98,278.00	\$2,063,845.00	01-Oct-16	30-Sep-18
Neurology	Escolar, Maria	Legacy of Angels Foundation	A Pilot Engraftment Study in Immunosuppressed Rats	\$62,354.00	\$3,118.00	\$65,472.00	01-Oct-16	30-Sep-17
Neurology	Goldstein, Amy	National Institutes of Health	Creating Models of Rare Childhood Liver Diseases Using the Human Liver Chip	\$1,238.00	\$669.00	\$1,907.00	01-Jul-16	30-Jun-17
Neurology	Goldstein, Amy	Columbia University	North American Mitochondrial Disease Consortium	\$1,299.00	\$701.00	\$2,000.00	01-Sep-13	31-Aug-17
Neurology	Pandey, Udai	Johns Hopkins University	Investigating the Molecular Mechanisms of FUS-Related ALS	\$0.00	\$0.00	\$0.00	01-Apr-14	31-Dec-17
Pulmonology	Alcorn, John	National Institutes of Health	Immature Infant Alveolar Macrophage Clearance of Cell Debris during RSV Infection	\$378.00	\$204.00	\$582.00	01-Apr-15	30-Jun-17
Pulmonology	Alcorn, John	National Institutes of Health	Basic and Clinical Studies of Cystic Fibrosis	\$0.00	\$0.00	\$0.00	01-Jul-15	31-May-18
Pulmonology	Alcorn, John	American Heart Association	The Role of the Receptor for Advanced Glycation Endproducts in Asthma	\$7,492.00	\$749.00	\$8,241.00	01-Jul-15	30-Jun-17

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Pulmonology	Celedon, Juan C.	Massachusetts General Hospital	Airway Microbiome and Age 6y Asthma Phenotypes in Two Diverse Multicenter Cohorts	\$4,583.00	\$2,486.00	\$7,069.00	01-Sep-16	31-Aug-23
Pulmonology	Celedon, Juan C.	Icahn School of Medicine at Mt. Sinai	Pulmonary Diseases in WTC Workers: Symptoms, Function, and Chest CT Correlates	\$22,915.00	\$12,432.00	\$35,347.00	01-Sep-16	31-Aug-17
Pulmonology	Celedon, Juan C.	Massachusetts General Hospital	Infant Specific-IgE, Rhinovirus-C Bronchiolitis, and Incident Asthma in MARC-35	\$2,214.00	\$1,196.00	\$3,410.00	01-Dec-14	30-Nov-19
Pulmonology	Celedon, Juan C.	Massachusetts General Hospital	Nasal MicroRNA during Bronchiolitis and Age 6y Asthma Phenotypes: MARC-35 Cohort	\$6,870.00	\$3,752.00	\$10,622.00	01-Dec-16	30-Nov-21
Pulmonology	Larkin, Allyson	National Institutes of Health	Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma	\$33,011.00	\$17,001.00	\$50,012.00	09-Aug-11	31-May-17
Pulmonology	Orenstein, David	National Institutes of Health	Basic and Translational Studies of Cystic Fibrosis, Core B	\$9,908.00	\$5,350.00	\$15,258.00	01-Jul-15	31-May-18
Pulmonology	Orenstein, David	Seattle Children's Hospital	OPTIMIZING Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter Randomized Trial, Clinical Coordinating Center	\$22,283.00	\$8,175.00	\$30,458.00	15-Sep-13	30-Jun-18
Pulmonology	Orenstein, David	Seattle Children's Hospital	The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF, Year 6-10	\$12,818.00	\$1,026.00	\$13,844.00	01-Sep-13	31-Aug-18
Pulmonology	Orenstein, David	Cystic Fibrosis Foundation	ACTIVATE-CF: Effects of a Six-Month Partially Supervised Conditioning Program in CF: An International Multicenter, Randomized, Controlled Trial	\$0.00	\$0.00	\$0.00	01-Nov-14	31-Oct-17
Pulmonology	Orenstein, David	Cystic Fibrosis Foundation	University of Pittsburgh Additional TDN Coordinator Support	\$0.00	\$0.00	\$0.00	01-Dec-14	30-Nov-17
Pulmonology	Pilewski, Joseph	Seattle Children's Hospital	Proof of Principal Evaluation of IV Gallium Nitrate in Patients with Cystic Fibrosis	\$40,386.00	\$3,231.00	\$43,617.00	01-Jul-16	30-Jun-17
Pulmonology	Pilewski, Joseph	Seattle Children's Hospital	Testing the Effect of Adding Chronic Azithromycin to Inhaled Tobramycin: A Randomized, Placebo-Controlled, Double-Blinded Trial of Azithromycin 500 MG Thrice Weekly in Combination with Inhaled Tobramycin Study	\$9,700.00	\$776.00	\$10,476.00	01-Jan-16	31-Dec-18
Pulmonology	Pilewski, Joseph	Seattle Children's Hospital	Standardized Treatment of Pulmonary Exacerbations II	\$5,945.00	\$475.00	\$6,420.00	01-Jan-16	31-Dec-18
Pulmonology	Pilewski, Joseph	Cystic Fibrosis Foundation	Additional Research Coordinator Award	\$39,122.00	\$3,130.00	\$42,252.00	01-Jan-16	31-Dec-17
Pulmonology	Pilewski, Joseph	Cystic Fibrosis Foundation	Translational Therapeutics Development Center	\$192,529.00	\$15,402.00	\$207,931.00	01-Jan-17	31-Dec-17
Pulmonology	Spahr, Jonathan	Cystic Fibrosis Foundation	CFF First- and Second-Year Clinical Fellowship	\$62,144.00	\$0.00	\$62,144.00	01-Jul-15	30-Jun-17
Pulmonology	Wang, Jieru	National Institutes of Health	Combined Viral and Bacterial Infection and Zinc Homeostasis in Distal Lung	\$13,202.00	\$7,129.00	\$20,331.00	01-Apr-15	31-Mar-20
Pulmonology	Weiner, Daniel	Department of Defense	Respiratory Ciliary Dysfunction and Pulmonary Risks in Congenital Heart Disease Patients	\$2,443.00	\$1,319.00	\$3,762.00	30-Sep-15	29-Sep-18
Pulmonology	Weiner, Daniel	Seattle Children's Hospital	A Two-Part, Multicenter, Prospective, Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis	\$0.00	\$0.00	\$0.00	01-Jul-14	01-Jun-18
Pulmonology	Weiner, Daniel	Seattle Children's Hospital	Saline Hypertonic in Preschoolers	\$7,806.00	\$624.00	\$8,430.00	01-Nov-14	31-Oct-18
Pulmonology	Weiner, Daniel	Cystic Fibrosis Foundation	Implementation of the Depression and Anxiety Guidelines: Award for a Mental Health Coordinator	\$50,000.00	\$4,000.00	\$54,000.00	01-Jan-16	31-Dec-18
Pulmonology	Weiner, Daniel	Cystic Fibrosis Foundation	Outpatient Clinical Pharmacy Services	\$52,000.00	\$4,160.00	\$56,160.00	01-Nov-16	31-Oct-19

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Rheumatology	Brunner, Emily	Cure JM Foundation	Stepping It Up: Physical Activity Monitors as Outcome Measures in Juvenile Myositis	\$26,667.00	\$0.00	\$26,667.00	01-Dec-16	30-Jun-18
Rheumatology	Rosenkranz, Margalit	Children's Hospital Medical Center	Gene Expression in Pediatric Arthritis	\$0.00	\$0.00	\$0.00	01-Sep-12	31-Aug-17
Rheumatology	Torok, Kathryn	Nancy Taylor Foundation for Chronic Diseases, Inc.	Serum Cytokine Profiles in Localized Scleroderma	\$152,963.00	\$9,037.00	\$162,000.00	01-Sep-16	31-Aug-18
Rheumatology	Torok, Kathryn	Scleroderma Foundation	Identifying Juvenile Scleroderma Immunophenotyped Subsets	\$243,219.00	\$19,458.00	\$262,677.00	01-Apr-16	31-Mar-18
Rheumatology	Vallejo, Abbe	National Institutes of Health	Translational Evaluation of Aging, Inflammation, and HIV in Lung Dysfunction	\$9,188.00	\$4,962.00	\$14,150.00	04-Sep-13	30-Jun-18
Rheumatology	Vallejo, Abbe	Nancy Taylor Foundation for Chronic Diseases, Inc.	Maladaptive DN T Cells in Juvenile Idiopathic Arthritis	\$150,000.00	\$12,000.00	\$162,000.00	01-Aug-10	31-Jul-17
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Immune Airway-Epithelial Interactions in Steroid-Refractory Severe Asthma	\$173,212.00	\$93,534.00	\$266,746.00	01-Jun-15	31-May-20
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Basic and Clinical Studies of Cystic Fibrosis, Core B	\$26,213.00	\$14,155.00	\$40,368.00	01-Jul-15	31-May-18
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Lung Epithelial-Immune Interactions in Respiratory Virus Infection	\$15,146.00	\$8,179.00	\$23,325.00	15-Aug-15	31-May-19
Richard King Mellon Foundation Institute	Kolls, Jay	Tulane University Health Sciences Center	IL-22: A Therapeutic Cytokine for the Amelioration of Pulmonary Inflammation	\$11,255.00	\$6,148.00	\$17,403.00	01-Aug-15	30-Nov-18
Richard King Mellon Foundation Institute	Kolls, Jay	Cystic Fibrosis Foundation	Transcriptomic Responses to Kalydeco: Role in Predicting Outcomes	\$100,000.00	\$8,000.00	\$108,000.00	01-Jan-16	31-Dec-17
Richard King Mellon Foundation Institute	Kolls, Jay	Cystic Fibrosis Foundation	Genome-Wide Analyses of Epigenetic Landscape of CF Airways	\$50,000.00	\$4,000.00	\$54,000.00	01-Apr-16	31-Mar-18
Weight Management and Wellness	Arslanian, Silva	Wake Forest University	B-Cell Function and Cognition in the Restoring Insulin Secretion Study	\$24,125.00	\$13,028.00	\$37,153.00	01-Sep-13	31-Aug-17
Weight Management and Wellness	Hughan, Kara	National Institutes of Health	Nitrite Benefits to Mediate Fatigability in Older HfpEF Patients	\$2,628.00	\$1,419.00	\$4,047.00	15-Aug-16	31-Jul-17
Weight Management and Wellness	Hughan, Kara	Cystic Fibrosis Foundation	Nitrite Modulation of Mitochondrial Function and Insulin Sensitivity in Patients with Cystic Fibrosis	\$29,059.00	\$2,325.00	\$31,384.00	01-Sep-16	31-Aug-19
Rheumatology	Rosenkranz, Margalit	Children's Hospital Medical Center	Gene Expression in Pediatric Arthritis	\$0.00	\$0.00	\$0.00	01-Sep-12	31-Aug-17
Rheumatology	Rosenkranz, Margalit	Duke University	Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry	\$82,600.00	\$20,650.00	\$103,250.00	01-Jul-15	30-Jun-16
Rheumatology	Torok, Kathryn	Rheumatology Research Foundation	Immunophenotyping Active Disease in Localized Scleroderma	\$50,000.00	\$0.00	\$50,000.00	15-Sep-14	31-Oct-16
Rheumatology	Torok, Kathryn	Scleroderma Foundation	Identifying Juvenile Scleroderma Immunophenotype Subsets	\$228,697.00	\$8,626.00	\$237,323.00	01-Apr-16	31-Mar-18
Rheumatology	Vallejo, Abbe	National Institutes of Health	Translational Evaluation of Aging, Inflammation, and HIV in Lung Dysfunction	\$9,114.00	\$4,922.00	\$14,036.00	04-Sep-13	30-Jun-18
Rheumatology	Vallejo, Abbe	Nancy Taylor Foundation for Chronic Diseases, Inc.	Maladaptive DN T cells in Juvenile Idiopathic Arthritis	\$150,000.00	\$12,000.00	\$162,000.00	01-Aug-10	31-Jul-17
Rheumatology	Vallejo, Abbe	American Federation for Aging Research	Thymic Preservation and Immune Function in a Long-Lived Mouse Model	\$125,000.00	\$12,500.00	\$137,500.00	01-Jul-12	30-Jun-16
Rheumatology	Vallejo, Abbe	CR Way	CR Way Immune Pilot Study of Successful Aging	\$36,000.00	\$0.00	\$36,000.00	01-May-16	30-Nov-16
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Mesenchymal Stem Cell Secretome in Lung Fibrosis: Mitochondria and RNA Shuttle	\$11,089.00	\$5,989.00	\$17,078.00	01-Jul-13	30-Jun-16

FOUNDATIONS AND OTHER FUNDING (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Immune Airway–Epithelial Interactions in Steroid-refractory Severe Asthma	\$174,000.00	\$91,530.00	\$265,530.00	01-Jun-15	31-May-20
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Basic and Clinical Studies of Cystic Fibrosis—Core B	\$31,180.00	\$16,837.00	\$48,017.00	01-Jul-15	30-Jun-20
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Lung Epithelial–Immune Interactions in Respiratory Virus Infection	\$14,235.00	\$7,687.00	\$21,922.00	15-Aug-15	31-May-19
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Lung Epithelial–Immune Interactions in Respiratory Virus Infection	\$14,874.00	\$8,032.00	\$22,906.00	15-Aug-15	31-May-19
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Mechanisms of IL-17–Mediated Host Defense in the Kidney	\$4,221.00	\$2,279.00	\$6,500.00	20-Sep-15	30-Jun-16
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	Understanding Severe Asthma Using an Experimental Mouse Model	\$14,611.00	\$7,890.00	\$22,501.00	07-Jan-13	31-Jan-17
Richard King Mellon Foundation Institute	Kolls, Jay	National Institutes of Health	UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)	\$22,915.00	\$12,375.00	\$35,290.00	24-Sep-14	31-May-17
Richard King Mellon Foundation Institute	Kolls, Jay	Tulane University Health Sciences Center	IL-22: A Therapeutic Cytokine for the Amelioration of Pulmonology Influenza Injury	\$6,445.00	\$3,480.00	\$9,925.00	01-Aug-15	30-Nov-18
Richard King Mellon Foundation Institute	Kolls, Jay	Fondazione Centro San Raffaele	Targeting IL17-Producing T Cells during <i>Pseudomonas aeruginosa</i> Lung Disease	\$4,597.00	\$368.00	\$4,965.00	01-Apr-16	31-Mar-18
Richard King Mellon Foundation Institute	Kolls, Jay	Cystic Fibrosis Foundation	RDP Renewal–Core B–Clinical Studies Core	\$22,220.00	\$0.00	\$22,220.00	01-Jul-15	30-Jun-16
Richard King Mellon Foundation Institute	Kolls, Jay	Cystic Fibrosis Foundation	Transcriptomic Responses to Kalydeco—Role in Predicting Outcomes	\$100,000.00	\$8,000.00	\$108,000.00	01-Jan-16	31-Dec-17
Richard King Mellon Foundation Institute	Kolls, Jay	Cystic Fibrosis Foundation	Genome-wide Analyses of Epigenetic Landscape of Cystic Fibrosis Airways	\$50,000.00	\$4,000.00	\$54,000.00	01-Apr-16	31-Mar-18
Richard King Mellon Foundation Institute	Kuhn, Bernhard	University of Pennsylvania	Role of Single-Cell mRNA Variation in Systems Associated Electrically Excitable C	\$215,000.00	\$116,100.00	\$331,100.00	01-Sep-14	31-May-17
Richard King Mellon Foundation Institute	Kuhn, Bernhard	Fondation Leducq	Elicitin Heart Regeneration through Cardiomyocyte	\$105,050.00	\$10,505.00	\$115,555.00	24-Feb-16	23-Feb-17
Weight Management and Wellness	Arslanian, Silva	Wake Forest University	B-Cell Function and Cognition in the Restoring Insulin Secretion (RISE) Study	\$24,125.00	\$13,028.00	\$37,153.00	01-Sep-13	31-Aug-17

INDUSTRY-SPONSORED STUDIES

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Allergy and Immunology	Green, Todd	DBV Technologies	A Double-Blind, Placebo-Controlled, Randomized Trial to Study the Viaskin Milk Efficacy and Safety for Treating IgF-Mediated Cow's Milk Allergy in Children	\$140,738.00	\$35,185.00	\$175,923.00	17-Jul-15	16-Jul-17
Bone Marrow Transplant/Cell Therapy	Vander Lugt, Mark	Chimerix	A Phase 3, Open-Label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir (CMX001) for the Prevention of Adenovirus (AdV) Disease in Subjects with Asymptomatic AdV Infection at Risk of Progression and for the Treatment of Subjects	\$97,224.00	\$26,943.00	\$124,167.00	01-Dec-14	31-Dec-17
Endocrinology	Escobar, Oscar	Endo Pharmaceuticals	A Multicenter, Observational Registry of Pediatric Female Subjects with Central Precocious Puberty Receiving Supprelin La (Histrelin Acetate), a Hydrogen Subcutaneous Implant	\$0.00	\$0.00	\$0.00	25-Sep-13	24-Sep-18
Endocrinology	Escobar, Oscar	Versartis, Inc.	An Open-Label, Long-Term Safety Study of Long-Acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone, PED-16-028	\$49,736.00	\$13,934.00	\$63,670.00	01-Dec-16	30-Nov-18
Gastroenterology	King, Dale	Chiltern International, Inc.	A Safety and Efficacy Study of a Bowel-Cleansing Preparation (BL1800) in Pediatric Subjects Undergoing Colonoscopy (PED-16-020)	\$43,649.00	\$10,912.00	\$54,561.00	24-Oct-16	30-Jun-17
Gastroenterology	Rudolph, Jeffrey	Fresenius Kabi Deutschland GmbH	A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 days of Parenteral Nutrition	\$329,912.00	\$82,103.00	\$412,015.00	17-Mar-16	31-Jan-18
Gastroenterology	Shah, Sapana	Janssen Research and Development, LLC	A Phase 4, Multicenter, Open-Label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients with Inflammatory Bowel Disease	\$102,111.00	\$25,153.00	\$127,264.00	19-Apr-16	31-Aug-18
Gastroenterology	Squires, Robert	Lumena Pharmaceuticals, Inc.	Therapeutic Effect of LUM001-Letter Agreement IMAGE	\$0.00	\$0.00	\$0.00	01-Sep-15	31-Aug-17
Gastroenterology	Srinath, Arvid	Forest Research Institute, Inc.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 7 to 17 Years, with Irritable Bowel Syndrome with Constipation	\$26,877.00	\$6,720.00	\$33,597.00	08-Mar-16	31-Dec-17
Gastroenterology	Srinath, Arvid	Forest Research Institution, Inc.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation	\$21,916.00	\$5,479.00	\$27,395.00	08-Mar-16	31-Dec-17
General Academic Pediatrics	Hoberman, Alejandro	MedImmune, Inc.	A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody with an Extended Half-Life against Respiratory Syncytial Virus, in Healthy Preterm Infants	\$319,073.00	\$79,768.00	\$398,841.00	01-Nov-16	01-Nov-17
Genetics	Gonzalez, Lina	Horizon Therapeutics, Inc.	Characterization of the Burden of Genetic Disease in Mercer County Amish	\$90,483.00	\$22,621.00	\$113,104.00	01-Mar-16	28-Feb-18
Genetics	Vockley, Gerard	Pfizer	A Multicenter, Multicounty, Post-Marketing Active Surveillance Taliglucerase Alpha Registry in Patients with Gaucher Disease	\$0.00	\$0.00	\$0.00	16-Jul-14	15-Jul-17

INDUSTRY-SPONSORED STUDIES (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Genetics	Vockley, Gerard	Stealth BioTherapeutics Inc.	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects with Genetically Confirmed Mitochondrial Disease Previously Treated	\$117,195.00	\$29,295.00	\$146,490.00	16-Aug-16	15-Aug-18
Genetics	Vockley, Gerard	Reata Pharmaceuticals, Inc.	A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy	\$189,217.00	\$47,304.00	\$236,521.00	28-Jul-15	27-Jul-17
Genetics	Vockley, Gerard	PROTALIX	A Randomized, Double-Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated with Agalsidase Beta	\$269,591.00	\$67,398.00	\$336,989.00	11-Jan-17	11-Jan-19
Genetics	Vockley, Gerard	ArmaGen, Inc.	An Extension Study of AGT-181-102 Evaluating Safety and Glycosaminoglycans (GAGS) in Adult Patients with Hurler-Scheie or Scheie Syndrome Who Have Completed Eight Weeks of Dosing with AGT-181 in Study AGT-181-102	\$66,153.00	\$16,538.00	\$82,691.00	31-Mar-16	30-Mar-18
Genetics	Vockley, Gerard	Alexion Pharmaceuticals	An Observational, Longitudinal, Prospective, Long-Term Registry of Patients with Hypophosphatasia	\$24,900.00	\$6,225.00	\$31,125.00	19-Oct-15	18-Oct-17
Genetics	Vockley, Gerard	Shire Human Genetic Therapies, Inc.	An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT, Administered in Conjunction with Intravenous Elaprase, in Pediatric Patients with Hunter Syndrome and Early Cognitive Impairment	\$0.00	\$0.00	\$0.00	01-Feb-13	28-Feb-18
Genetics	Vockley, Gerard	Alexion Pharmaceuticals	An Open-Label, Multicenter, Expanded Access Program for Asfotase Alfa (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients with Infantile or Juvenile-Onset Hypophosphatasia (HPP)	\$34,099.00	\$8,525.00	\$42,624.00	07-Oct-15	06-Oct-17
Genetics	Vockley, Gerard	BioMarin Pharmaceuticals, Inc.	Burden of PAH Deficiency/PKU among Adults: A Retrospective Chart Review and Cross-Sectional Patient Survey	\$9,790.00	\$2,447.00	\$12,237.00	07-Nov-16	06-Nov-18
Genetics	Vockley, Gerard	Hyperion Therapeutics, Inc.	Long-Term Registry of Patients with Urea Cycle Disorders	\$30,396.00	\$7,524.00	\$37,920.00	18-Sep-13	17-Sep-23
Genetics	Vockley, Gerard	ICON Clinical Research, LLC	The Clinical and Economic Burden of Illness of MPS II (Hunter Syndrome) in the United States	\$7,170.00	\$1,793.00	\$8,963.00	17-Oct-16	16-Oct-18
Genetics	Vockley, Gerard	Ultragenyx Pharmaceuticals, Inc.	Dietary Therapy for Inherited Disorders of Mitochondrial Fatty Acid Oxidation and Glycogenoses	\$18,902.00	\$4,725.00	\$23,627.00	02-Aug-13	30-Jun-18
Genetics	Vockley, Gerard	Moderna TX, Inc.	MCAD Study	\$195,492.00	\$120,227.00	\$315,719.00	11-Oct-16	10-Oct-18
Genetics	Vockley, Gerard	Moderna TX, Inc.	VLCAD Study	\$200,492.00	\$123,302.00	\$323,794.00	11-Oct-16	10-Oct-18
Hematology/Oncology	Cohen, Debra	Mast Therapeutics, Inc.	An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects with Sickle Cell Disease Experiencing Vaso-Occlusive Crisis	\$35,834.00	\$8,708.00	\$44,542.00	23-Mar-16	22-Mar-19
Hematology/Oncology	Cohen, Debra	Pfizer	PED-15-015: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects with Sickle Cell Disease	\$33,142.00	\$8,036.00	\$41,178.00	01-Sep-16	31-Aug-19

INDUSTRY-SPONSORED STUDIES (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Hematology/ Oncology	Cohen, Debra	Pfizer	PED-15-016: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI 1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects with Sickle Cell Disease	\$36,740.00	\$8,575.00	\$45,315.00	01-Nov-16	31-Oct-18
Hematology/ Oncology	Malec, Lynn	Biogen MA, Inc.	Recombinant Factor VIII Fc Fusion Protein, rFVIII-Fc, in Immune Tolerance Induction in Hemophilia A Patients with Inhibitors	\$19,427.00	\$4,857.00	\$24,284.00	12-May-16	30-Apr-19
Hematology/ Oncology	Ritchey, Kim	Amgen Corporation	A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune Thrombocytopenia	\$111,438.00	\$27,453.00	\$138,891.00	01-Oct-15	30-Sep-18
Nephrology	Ellis, Demetrius	AVI BioPharma	Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsin in Subjects with Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201	\$14,429.00	\$3,297.00	\$17,726.00	01-Jun-12	31-May-18
Neurology	Abdel-Hamid, Hoda	AVI BioPharma, Inc.	Open-Label, Multiple-Dose Efficacy, Safety, and Tolerability Study of Eteplirsin in Patients with Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201	\$14,430.00	\$3,297.00	\$17,727.00	01-Jun-12	31-May-18
Neurology	Escolar, Maria	Synageva BioPharma Corporation	A Phase I/II Open-Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of SBC-103 Administered Intravenously	\$415,342.00	\$103,585.00	\$518,927.00	17-Dec-14	16-Dec-17
Neurology	Goldstein, Amy	Stealth BioTherapeutics, Inc.	A Prospective, Observational Study of Patients with Primary Mitochondrial Disease	\$33,919.00	\$8,480.00	\$42,399.00	30-Jan-17	30-Jan-19
Pulmonology	Alcorn, John	MedImmune, Inc.	Efficacy of Novel Antibodies against Influenza, <i>Staphylococcus aureus</i> Super-Infection	\$89,369.00	\$54,961.00	\$144,330.00	03-Jun-16	02-Jun-18
Pulmonology	Orenstein, David	Vertex	A Phase 3, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 6 through 11 Years with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	\$49,260.00	\$12,315.00	\$61,575.00	27-Oct-15	26-Oct-17
Pulmonology	Orenstein, David	Anthera Pharmaceuticals, Inc.	A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency	\$30,581.00	\$7,646.00	\$38,227.00	09-Dec-15	08-Dec-17
Pulmonology	Orenstein, David	Alcresta Pharmaceuticals, Inc.	Study to Evaluate Safety, Tolerability, and Fat Absorption Using a Novel Enteral Feeding In-Line Digestive Enzyme Cartridge (RELIZORB) in Patients with Cystic Fibrosis Receiving Enteral Feeding	\$22,491.00	\$5,623.00	\$28,114.00	19-May-16	18-May-18
Pulmonology	Orenstein, David	Alcresta Pharmaceuticals, Inc.	Study to Evaluate Safety, Tolerability, and Fat Absorption Using a Novel Enteral Feeding In-Line Digestive Enzyme Cartridge in Patients with Cystic Fibrosis Receiving Enteral Feeding	\$22,035.00	\$5,509.00	\$27,544.00	21-Dec-15	20-Dec-17
Pulmonology	Pilewski, Joseph	Celtaxsys, Inc.	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once Daily for 48 Weeks in Adult Patients with Cystic Fibrosis	\$36,419.00	\$9,105.00	\$45,524.00	17-Feb-16	16-Feb-18

INDUSTRY-SPONSORED STUDIES (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Pulmonology	Pilewski, Joseph	Nivalis Therapeutics	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation and Being Treated with Lumacaftor/Ivacaftor	\$22,777.00	\$5,695.00	\$28,472.00	14-Jun-16	13-Jun-18
Pulmonology	Pilewski, Joseph	Nivalis Therapeutics	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation and Being Treated with Lumacaftor/Ivacaftor	\$38,426.00	\$9,607.00	\$48,033.00	15-Jan-16	14-Jan-18
Pulmonology	Pilewski, Joseph	Vertex	A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated with Orkambi	\$57,242.00	\$14,311.00	\$71,553.00	26-May-16	25-May-18
Pulmonology	Pilewski, Joseph	Vertex	A Phase 3, Open-Label, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment with VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	\$57,011.00	\$14,253.00	\$71,264.00	28-Oct-15	27-Oct-17
Pulmonology	Pilewski, Joseph	Seattle Children's Hospital	G551D Observational (GOAL) Study	\$15,908.00	\$1,272.00	\$17,180.00	01-Sep-11	31-Dec-20
Pulmonology	Weiner, Daniel	RespirTech Technologies	Peak Cough Flow and Airway Clearance in Pediatric Neuromuscular Disease	\$0.00	\$0.00	\$0.00	01-Aug-13	31-Jul-18
Rheumatology	Kietz, Daniel	Bristol-Myers Squibb	An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis	\$34,236.00	\$10,171.00	\$44,407.00	01-May-13	30-Apr-23
Rheumatology	Rosenkranz, Margalit	Pfizer	A Long-Term, Open-Label Follow-Up Study of CP-690, 550 for Treatment of Juvenile Idiopathic Arthritis	\$7,695.00	\$1,799.00	\$9,494.00	24-Sep-15	20-Mar-22
Rheumatology	Rosenkranz, Margalit	Pfizer	Efficacy, Safety, and Tolerability of Tofacitinib for Treatment of Polyarticular Course Juvenile Idiopathic Arthritis in Children and Adolescent Subjects	\$55,024.00	\$13,756.00	\$68,780.00	11-Jan-17	10-May-19
Rheumatology	Rosenkranz, Margalit	Pfizer	Efficacy, Safety, and Tolerability of Tofacitinib for Treatment of Polyarticular Course Juvenile Idiopathic Arthritis in Children and Adolescent Subjects	\$55,025.00	\$13,756.00	\$68,781.00	11-Jan-17	10-May-19
Richard King Mellon Foundation Institute	Kolls, Jay	Novartis Pharmaceuticals	Exploring Antibody-Mediated B-Cell Depletion and Impact of PCP in Mice	\$52,439.00	\$32,250.00	\$84,689.00	15-Sep-16	14-Sep-17
Weight Management and Wellness	Arslanian, Silva	Novo Nordisk Pharmaceuticals, Inc.	Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects with Obesity: A 56-Week, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Multinational Trial Followed by a 26-Week Period off Study Drug, Phase 3a	\$96,592.00	\$24,148.00	\$120,740.00	20-Jan-17	19-Jan-19
Weight Management and Wellness	Hughan, Kara	Boehringer Ingelheim Pharmaceuticals, Inc.	An Open-Label, Randomized, Multicenter, Single-Dose, Parallel-Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents from 10 to Less Than 18 Years of Age with Type 2 Diabetes Mellitus	\$0.00	\$0.00	\$0.00	15-Aug-14	14-Aug-17
Weight Management and Wellness	Ismail, Heba	Novo Nordisk Pharmaceuticals, Inc.	A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years	\$27,628.00	\$6,907.00	\$34,535.00	03-Jun-16	02-Jun-18

INDUSTRY-SPONSORED STUDIES (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Weight Management and Wellness	Ismail, Heba	Novo Nordisk Pharmaceuticals, Inc.	Efficacy and Safety of Faster-Acting Insulin Aspart Compared to NovoRapid Both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes	\$128,860.00	\$32,215.00	\$161,075.00	29-Jun-16	28-Jun-18
Pulmonology	Orenstein, David	Alcresta Pharmaceuticals, Inc.	Study to Evaluate Safety, Tolerability, and Fat Absorption Using a Novel Enteral Feeding In-Line Digestive Enzyme Cartridge (RELIZORB) in Patients with Cystic Fibrosis Receiving Enteral Feeding	\$22,491.00	\$5,622.00	\$28,113.00	19-May-16	18-May-18
Pulmonology	Orenstein, David	Alcresta Pharmaceuticals, Inc.	Study to Evaluate Safety, Tolerability, and Fat Absorption Using a Novel Enteral Feeding In-Line Digestive Enzyme Cartridge in Patients with Cystic Fibrosis Receiving Enteral Feeding	\$36,335.00	\$9,084.00	\$45,419.00	21-Dec-15	20-Dec-17
Pulmonology	Pilewski, Joseph	Vertex	A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Exploratory Study to Evaluate Effects of VX-661 in Combination with Ivacaftor on Lung and Extrapulmonary Systems in Subjects Aged 18 Years and Older with Cystic Fibrosis	\$127,997.00	\$31,999.00	\$159,996.00	23-Nov-15	22-Nov-16
Pulmonology	Pilewski, Joseph	Celtaxsys, Inc.	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once Daily for 48 Weeks in Adult Patients with Cystic Fibrosis	\$36,419.00	\$9,105.00	\$45,524.00	17-Feb-16	16-Feb-18
Pulmonology	Pilewski, Joseph	Nivalis Therapeutics	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation and Being Treated with Lumacaftor/Ivacaftor	\$22,776.00	\$5,694.00	\$28,470.00	14-Jun-16	13-Jun-18
Pulmonology	Pilewski, Joseph	Nivalis Therapeutics	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation and Being Treated with Lumacaftor/Ivacaftor	\$38,426.00	\$9,606.00	\$48,032.00	15-Jan-16	14-Jan-18
Pulmonology	Pilewski, Joseph	Vertex	A Phase 2a, Randomized, Double-Blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older with Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated with Orkambi	\$57,242.00	\$14,310.00	\$71,552.00	26-May-16	25-May-18
Pulmonology	Pilewski, Joseph	Vertex	A Phase 3, Open-Label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	\$57,010.00	\$14,252.00	\$71,262.00	28-Oct-15	27-Oct-17
Pulmonology	Pilewski, Joseph	Vertex	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis	\$56,337.00	\$14,085.00	\$70,422.00	26-Jun-15	25-Jun-17
Pulmonology	Pilewski, Joseph	Vertex	A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older with Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR Mutation	\$26,341.00	\$7,741.00	\$34,082.00	05-Mar-15	04-Mar-17

INDUSTRY-SPONSORED STUDIES (continued)

DIVISION	NAME	AGENCY TITLE	TITLE	ANNUAL DIRECT COST	ANNUAL INDIRECT COST	ANNUAL TOTAL COST	GRANT BEGIN DATE	GRANT END DATE
Pulmonology	Pilewski, Joseph	Seattle Children's Hospital	G551D Observational (GOAL) Study	\$32,345.00	\$1,787.00	\$34,132.00	01-Sep-11	31-Dec-20
Pulmonology	Weiner, Daniel	RespirTech Technologies	Peak Cough Flow and Airway Clearance in Pediatric Neuromuscular Disease	\$0.00	\$0.00	\$0.00	01-Aug-13	31-Jul-18
Rheumatology	Kietz, Daniel	Bristol-Myers Squibb	An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis	\$34,236.00	\$10,171.00	\$44,407.00	01-May-13	30-Apr-23
Rheumatology	Rosenkranz, Margalit	Pfizer	A Long-term, Open-Label Follow-up Study of CP-690, 550 for Treatment of Juvenile Idiopathic Arthritis (JIA)	\$7,693.00	\$1,799.00	\$9,492.00	24-Sep-15	20-Mar-22
Richard King Mellon Foundation Institute	Kolls, Jay	Implicit Bioscience	Evaluation of ODS in Infection	\$11,886.00	\$7,310.00	\$19,196.00	11-Nov-15	10-Nov-16
Weight Management and Wellness	Hughan, Kara	Boehringer Ingelheim Pharmaceuticals, Inc.	An Open-Label, Randomized, Multicenter, Single-Dose, Parallel-Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents from 10 to Less Than 18 Years of Age with Type 2 Diabetes Mellitus	\$18,215.00	\$4,179.00	\$22,394.00	15-Aug-14	14-Aug-17
Weight Management and Wellness	Ismail, Heba	Novo Nordisk Pharmaceuticals, Inc.	A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics, and pPharmacodynamics of Liraglutide in Obese Children Aged Seven to 11 Years	\$41,768.00	\$10,442.00	\$52,210.00	03-Jun-16	02-Jun-18
Weight Management and Wellness	Ismail, Heba	Novo Nordisk Pharmaceuticals, Inc.	Efficacy and Safety of Faster-Acting Insulin Aspart Compared to NovoRapid Both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes	\$128,859.00	\$32,215.00	\$161,074.00	29-Jun-16	28-Jun-18

Notes